Editors’ Biographies
Downloaded by CORNELL UNIV on July 23, 2016 | http://pubs.acs.org Publication Date (Web): October 15, 2015 | doi: 10.1021/bk-2015-1201.ot001
John E. Schiel Dr. John E. Schiel received his B.S. (2004) and Ph.D. (2009) in Chemistry from the University of Nebraska-Lincoln, and is currently a research chemist in the NIST Biomolecular Measurement Division. He is leading the LC- and MS-based biomanufacturing research efforts at NIST; developing a suite of fundamental measurement science, standards, and reference data to enable more accurate and confident characterization of product quality attributes. Dr. Schiel is also the technical project coordinator for the recombinant IgG1κ NIST monoclonal antibody Reference Material (NISTmAb) program. He is an author of over 20 publications and recipient of numerous awards, including the ACS Division of Analytical Chemistry Fellowship, Bioanalysis Young Investigator Award, and UNL Early Achiever Award.
Darryl L. Davis Dr. Darryl L. Davis holds a doctorate in Medicinal Chemistry from the Philadelphia College of Pharmacy and Science. His thesis focused on the use of MS in the characterization and quantitation of peptide phosphorylation. He started his career at J&J as a COSAT intern using MS to characterize the glycan linkages found on Remicade. Upon receiving his doctorate he accepted a full-time position within the Bioanalytical Characterization group at Centocor, a J&J company. Since joining J&J he has held a wide variety of responsibilities including starting and leading several sub-groups, analytical CMC lead, member of CDTs, member of technology development teams for alternative production platforms and new technology and innovation lead within analytical development. He has won several innovation awards within J&J for his work on automation and high-throughput analysis which continues to be a current focus. Currently he leads an analytical group within the discovery organization at Janssen R&D.
Oleg V. Borisov Dr. Oleg V. Borisov earned a B.S. degree (with honors) in Chemistry at Moscow State University (1992), and received his Ph.D. in Chemistry from Wayne State University (1997), after which he completed his post-doctoral studies at Lawrence Berkeley National Laboratories (2000) and Pacific Northwest National Laboratories (2001). His background includes experience with analytical methods for characterization of biotherapeutic proteins and vaccine products, with emphasis on liquid chromatography and mass spectrometry methods. © 2015 American Chemical Society Schiel et al.; State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. ... ACS Symposium Series; American Chemical Society: Washington, DC, 2015.
Downloaded by CORNELL UNIV on July 23, 2016 | http://pubs.acs.org Publication Date (Web): October 15, 2015 | doi: 10.1021/bk-2015-1201.ot001
Dr. Borisov held positions at Genentech and Amgen with responsibilities that included protein characterization, testing improvement, leading innovation and CMC strategy teams. He is currently a Director at Novavax, Inc., developing methods and strategies for analysis and characterization of recombinant vaccines, based on nano- and virus-like particle technologies. His credits include several student awards, a book chapter, and over 25 scientific publications.
416 Schiel et al.; State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. ... ACS Symposium Series; American Chemical Society: Washington, DC, 2015.
